| SEC Form 4 | |
|------------|---|
| FORM | 4 |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
|--|
| |

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | |
|--------------------------|-----------|--|--|--|--|
| OMB Number: | 3235-0287 | | | | |
| Estimated average burden | | | | | |

hours per response: 0.5

| intended to satisfy the affirmative defense conditions of Rule 10b5- 1(c). See Instruction 10. | | | |
|--|------------------|--|---|
| 1. Name and Address of Reporting Pers Brazzell Romulus K | :on [*] | 2. Issuer Name and Ticker or Trading Symbol KALA BIO, Inc. [KALA] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify |
| (Last) (First) C/O KALA BIO, INC. 1167 MASSACHUSETTS AVEN | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/06/2025 | SEE REMARKS |
| (Street) ARLINGTON MA | 02476 | 4. If Amendment, Date of Original Filed (Month/Day/Year) 01/07/2025 | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person |
| (City) (State) | (Zip) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | e, Transaction Code (Instr. | | 4. Securities Disposed Of 5) | | | Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--|---|--------------------------------|---|------------------------------------|---------------|-------|--|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | (11150. 4) |
| Common Stock | | | | | | | | 91,636 ⁽¹⁾ | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | | | (e.g., pt | 113, 00 | ans, 1 | varie | anto, | options, t | | 10 30 | cunties | 7 | | | | | | | |
|---|---|--|---|------------------------------|--------|---|-------|---|--------------------|-------------------------------------|--|---|--|---|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | on of cr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 | | Expiration Date (Month/Day/Year) | | Derivative (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 | | Ind 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | | | |

Explanation of Responses:

1. This amendment is being filed solely to amend the securities as beneficially owned by the reporting person following the transactions previously reported on January 7, 2025. On January 7, 2025, the reporting person filed a Form 4 which inadvertently reported that, following the grant of restricted units and a sale of common stock, the reporting person held 92,418 shares. As reported in this amendment, the reporting person directly owned 91,636 shares of common stock following the transactions, which included 62,961 unvested restricted stock units

Remarks:

Head of Research and Development and Chief Medical Officer

| /s/ Mary Reumuth, Attorney- | 01/10/2025 |
|-----------------------------|------------|
| in-Fact | 01/10/2023 |

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.